Sprint Bioscience AB (publ) (FRA:5JA1)

Market Cap	42.38M +879.0%
Revenue (ttm)	13.97M +145.7%
Net Income	7.70M
EPS	0.08
Shares Out	n/a
PE Ratio	5.50
Forward PE	15.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3850
Previous Close	0.3540
Day's Range	0.3850 - 0.3850
52-Week Range	0.0228 - 0.3850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JA1

Financial Performance

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error